Clinical assessment of patients with acromegaly

Feyzi Gokosmanoglu, Attila Onmez
Department of Endocrinology, Sakarya University Medicine Faculty, Sakarya, 'Department of Internal Medicine, Duzce University Medicine Faculty, Duzce, Turkey

Background: In this study, we aimed to retrospectively evaluate treatment outcomes and treatment methods in acromegaly patients. Materials and Methods: The study included 65 acromegaly patients followed in Sakarya University Faculty of Medicine Department of Endocrinology in Turkey between 2004 and 2013. Clinical, biochemical, and radiological data were obtained retrospectively from the medical files of the patients. All cases have been discussed in the endocrinology and pituitary surgery council, and a multidisciplinary treatment approach had been chosen in management. Results: Sixty-five patients were included in the study. Of the patients, 57% were female. Mean age was 45.3 ± 9.2 years old. Of the cases, 12.3% were microadenomas (n = 8, tumor diameter <10 mm) and 87.6% were macroadenomas (n = 57, tumor diameter ≥10 mm). In our study, 70% remission was achieved with the first operation and medical treatment. Patients with invasive acromegaly without remission after the first operation underwent reoperation, medical treatment, and conventional or stereotactic radiotherapy and achieved 45% remission rate. Conclusion: Pituitary surgery is the first treatment option for acromegaly. In patients who could not be remissioned after the first operation, remission can be achieved by combined therapy consist of reoperation, medical treatment, and conventional or stereotactic radiotherapy.

Key words: Acromegaly, pituitary gland, treatment

INTRODUCTION

Pituitary adenomas make up more than 90% of all pituitary tumors. Growth hormone (GH)-secreting pituitary adenomas clinically present as acromegaly. Treatment of the disease includes surgical treatment, medical treatment, and radiotherapy. Surgery is the first-treatment option in most patients. Patients with heightened anesthesia risks may not be suited to surgical treatment. Medical treatment may be used first for these patients. Radiotherapy may be applied as adjuvant therapy in combination with medical therapy in patients with residual GH hypersecretion after surgical treatment. We aimed to retrospectively evaluate treatment outcomes for various treatment methods in acromegaly patients admitted to our clinic.

MATERIALS AND METHODS

The study included 65 acromegaly patients followed in Sakarya University Faculty of Medicine Department of Endocrinology in Turkey between 2004 and 2013. Clinical, biochemical, and radiological data were obtained retrospectively from the medical files of the patients. All cases have been discussed in the endocrinology and pituitary surgery council, and a multidisciplinary treatment approach had been chosen in management. Serum insulin-like growth factor 1 (IGF-1) levels were investigated in patients with clinical findings consistent with acromegaly. Oral glucose tolerance test (OGTT) was performed for GH measurements in patients who had supranormal serum IGF-1 level (age and sex-adjusted >2 standard deviations) second time. Rare GH >0.4 ng/mL was accepted as abnormal. Pituitary magnetic resonance imaging (MRI) was performed in patients with failure in GH suppression test, supranormal serum IGF-1 levels, and those who have high clinical suspicion for acromegaly diagnosis. The patients were divided into two groups, microadenoma (<10 mm) and macroadenoma (≥10 mm), according to tumor size as shown by MRI. Patients with basal serum GH levels <1 ng/ml and IGF-1 levels for the first 3–6 months after surgery which were normal

Access this article online

Quick Response Code:
Website: www.jmsjournal.net
DOI: 10.4103/jrms.JRMS_139_17

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Address for correspondence: Dr. Attila Onmez, Düzce Üniversitesi Tıp Fakültesi, Yörükler Mah., Konuralp yerleşkesi, 81620 Merkez/ Düzce, Turkey. E-mail: attilaonmez@duzce.edu.tr

Received: 02-03-2017; Revised: 13-01-2018; Accepted: 09-05-2018
according to age and gender, as well as GH levels <0.4 ng/ml in an OGTT, were considered to be in remission.\(^\text{[9]}\) The patients were classified according to categories including remission after surgical and medical therapies, remission after combination therapies, second-look operation due to progression after surgical and medical therapies, and absence of remission despite all therapies. The patients were operated by two surgeons experienced in pituitary tumor surgery.

**RESULTS**

A total of 65 patients were included in our study. Of the patients, 57\% (\(n = 37\)) were female and 43\% (\(n = 28\)) were male. Mean age was 45.3 ± 9.2. Complaints on admission were growing in hands-feet, chin (67.8\%), headache (18.7\%), and visual symptoms (7.8\%) [Table 1]. Of the cases, 12.3\% were microadenomas (\(n = 8\)), tumor diameter <10 mm), while 87.6\% were macroadenomas (\(n = 57\), tumor diameter ≥10 mm). Surgical treatment was applied to 91.6\% (\(n = 55\)) of the patients, while 92.7\% (\(n = 51\)) were operated by transsphenoidal approach. Reoperation was done for 18.1\% (\(n = 10\)) of the patients who received medical treatment after surgery. Of the patients, 25\% (\(n = 15\)) were treated with surgical treatment; 13.3\% (\(n = 8\)) with surgical and medical treatment. The ratio of the patients showing progression was 30\% (\(n = 18\)) [Table 2]. Medical treatments included octreotide long-acting release (LAR) (\(n = 25\)); octreotide LAR + pegvisomant (\(n = 6\)); and lanreotide autogel (\(n = 5\)) partial pituitary insufficiency were seen in 77.61\% (\(n = 52\)) of the study population. Oral administration of octreotide LAR 30 mg/28 days and deep intragluteal injection of lanreotide autogel 120 mg/28 days, pegvisomant 20 mg/day subcutaneous injection, and oral cabergoline 2–3 mg/week were administered for the medical treatment.

**DISCUSSION**

Acromegaly is a systemic disorder which influences many organs. It is clinically characterized by somatic impairment and systemic involvement. Enlargement of the hands, feet, and fingers and soft-tissue thickening are often seen.\(^\text{[8]}\) Enlargement in hands and feet, mandible (67.8\%), and headache (18\%) were the most common findings on admission in our study. The aim of acromegaly treatment is to normalize GH secretion, IGF-1 levels, correct signs and symptoms of the disease, prevent complications, control tumor growing, preserve anterior pituitary functions, and prevent tumor recurrence.\(^\text{[9]}\) In our study, surgical treatment was applied in 91.6\% of the patients. Reoperations were performed in 18.1\% of cases. Remission rates were found as 42%–70% in the studies done using endoscopic and microscopic transsphenoidal surgery and 2000 remission criteria.\(^\text{[10,11]}\) In our study, postoperative remission rates of the patients were found to be significantly lower than those reported in the literature. This is because the majority of the patients included in the study were challenging cases evaluated in the surgical and medical council for pituitary diseases. In addition, most of these cases seem to have undergone insufficient resection in their first operation. Postoperative residual adenomas were detected around the suprasellar region by pituitary MRI. The low remission rate with medical therapy is consistent with residual tumor presence. There are limited options for the patients not experiencing biochemical remission following their first operation. Alternative treatments include medical treatment, radiotherapy, and reoperation. When repeated surgical treatment options were compared, they were found to be more effective and safe in treatment of patients with uncontrolled acromegaly. Similar remission rates may be achieved.\(^\text{[12]}\) Combined treatment methods were applied to patients who did not have biochemical remission after the first operation. We found a remission rate of 45\% with combined therapy which was consists of surgery, medical treatment, and conventional or stereotactic radiotherapy. Long-acting somatostatin analogs (octreotide LAR,
lanreotide and autogel) may be used if a cure cannot be effected following surgical treatment. GH levels may decrease 69%–72%, along with a decrease in adenoma size and general improvement of symptoms. In our study, 7 years of remission were achieved with long-acting somatostatin analogs, cabergoline, pegvisomant, and conventional or radiotherapy in 36.6% patients who experienced recurrence after the first operation.

**CONCLUSION**

Pituitary surgery is the first treatment option for acromegaly in our clinic. In patients who could not be remissioned after the first operation, remission can be achieved by combined therapy consist of reoperation, medical treatment, and conventional or stereotactic radiotherapy.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**REFERENCES**

1. Manjila S, Wu OC, Khan FR, Khan MM, Arafah BM, Selman WR, et al. Pharmacological management of acromegaly: A current perspective. Neurosurg Focus 2010;29:E14.
2. Katznelson L, Atkinson JL, Cook DM, Ezzat SZ, Hamrahian AH, Miller KK, et al. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly–2011 update. Endocr Pract 2011;17 Suppl 4:1-44.
3. Mezosi E, Nemes O. Treatment of pituitary adenomas. Orv Hetil 2009;150:1803-10.
4. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al. Guidelines for acromegaly management: An update. J Clin Endocrinol Metab 2009;94:1509-17.
5. Cordido F, Garcia Arnés JA, Marazuela Aspiroz M, Torres Vela E. Practical guidelines for diagnosis and treatment of acromegaly. Endocrinol Nutr 2013;60:457.e1-457.e15.
6. Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, et al. A structural and functional acromegaly classification. J Clin Endocrinol Metab 2015;100:122-31.
7. Wang YY, Higham C, Kearney T, Davis JR, Trainer P, Granalingham KK, et al. Acromegaly surgery in manchester revisited – The impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clin Endocrinol (Oxf) 2012;76:399-406.
8. Chanson P, Salenave S. Acromegaly. Orphanet J Rare Dis 2008;3:17.
9. Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 2005;153:187-93.
10. Campbell PG, Kenning E, Andrews DW, Yadla S, Rosen M, Evans JJ, et al. Outcomes after a purely endoscopic transsphenoidal resection of growth hormone-secreting pituitary adenomas. Neurosurg Focus 2010;29:E5.
11. Shin SS, Tormenti MJ, Paluzzi A, Rothfus WE, Chang YF, Zainah H, et al. Endoscopic endonasal approach for growth hormone secreting pituitary adenomas: Outcomes in 53 patients using 2010 consensus criteria for remission. Pituitary 2013;16:435-44.
12. Wilson TJ, McKeen EL, Barkan AL, Chandler WF, Sullivan SE. Repeat endoscopic transsphenoidal surgery for acromegaly: Remission and complications. Pituitary 2013;16:435-44.
13. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001;86:2779-86.